Exploration of Pupil Dilation in Horner's Patients Taking Flomax
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03615508|
Recruitment Status : Terminated (incomplete enrollment)
First Posted : August 3, 2018
Results First Posted : October 14, 2020
Last Update Posted : October 14, 2020
|Condition or disease||Intervention/treatment||Phase|
|Horner Syndrome||Drug: 10% phenylephrine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Single arm, intervention trial.|
|Masking:||None (Open Label)|
|Official Title:||Exploration of Pupil Dilation in Horner's Patients Taking Flomax|
|Actual Study Start Date :||September 21, 2018|
|Actual Primary Completion Date :||May 1, 2019|
|Actual Study Completion Date :||May 1, 2019|
All patients will receive 10% phenylephrine at their eye examination as the drug to dilate the pupil. After pupil dilation, pupil size will be measured.
Drug: 10% phenylephrine
10% phenylephrine is a drug that can be used to dilate patient's eyes at their yearly eye examination. All enrolled subjects will receive this drug for their eye dilation.
Other Name: Phenylephrine 10%, Pupil Dilation
- Pupil Size Measurements [ Time Frame: 20-30 minutes after 10% phenylephrine has been placed in each eye. ]pupil dilation measurements will be taken of each eye at the eye examination.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03615508
|United States, Colorado|
|University of Colorado Hospital, Rocky Mountain Lions Eye Institute|
|Denver, Colorado, United States, 80023|
|Denver, Colorado, United States, 80024|
|Principal Investigator:||Cristos Ifantides, MD||Denver Health|